SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy a Prospective Exploratory Study
Latest Information Update: 03 Apr 2024
Price :
$35 *
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SABRE
- 10 Oct 2021 Planned End Date changed from 1 Dec 2023 to 1 Oct 2023.
- 10 Oct 2021 Planned primary completion date changed from 1 Jun 2022 to 1 Oct 2022.
- 10 Oct 2021 Planned initiation date changed from 1 Jun 2021 to 1 Oct 2021.